<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">
 <bold>Flexible Approaches.</bold> Regulators have adopted approaches to facilitating the continuity of clinical trials of both COVID-19–related medical products and ongoing or planned studies outside of COVID-19.
 <xref rid="bib16" ref-type="bibr">
  <sup>16</sup>
 </xref> Guidance on conducting clinical trials during the pandemic have been offered by several regulators
 <xref rid="bib17" ref-type="bibr">17</xref>, 
 <xref rid="bib18" ref-type="bibr">18</xref>, 
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib21" ref-type="bibr">21</xref>—many of which are nonbinding and require effective monitoring from the sponsor and clinical investigators. These approaches ensure that patient safety remains paramount and that open communication is maintained across the various stakeholders involved in clinical trials. Some of these approaches are further described in 
 <xref rid="tbl2" ref-type="table">Table II</xref> .
</p>
